Complementary strategies for developing Gd-free high-field T₁ MRI contrast agents based on Mn(III) porphyrins

J Med Chem. 2014 Jan 23;57(2):516-20. doi: 10.1021/jm401124b. Epub 2014 Jan 7.

Abstract

Mn(III) porphyrin (MnP) holds the promise of addressing the emerging challenges associated with Gd-based clinical MRI contrast agents (CAs), namely, Gd-related adverse effect and decreasing sensitivity at high clinical magnetic fields. Two complementary strategies for developing new MnPs as Gd-free CAs with optimized biocompatibility were established to improve relaxivity or clearance rate. MnPs with distinct and tunable pharmacokinetic properties can consequently be constructed for different in vivo applications at clinical field of 3 T.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biphenyl Compounds / chemical synthesis*
  • Biphenyl Compounds / chemistry
  • Biphenyl Compounds / pharmacokinetics
  • Contrast Media / chemical synthesis*
  • Contrast Media / chemistry
  • Contrast Media / pharmacokinetics
  • Coordination Complexes / chemical synthesis*
  • Coordination Complexes / chemistry
  • Coordination Complexes / pharmacokinetics
  • Gadolinium
  • Magnetic Resonance Imaging
  • Manganese*
  • Metalloporphyrins / chemical synthesis*
  • Metalloporphyrins / chemistry
  • Metalloporphyrins / pharmacokinetics
  • Porphyrins / chemical synthesis*
  • Porphyrins / chemistry
  • Porphyrins / pharmacokinetics
  • Rats
  • Structure-Activity Relationship

Substances

  • (5,10,15,20-tetrakis(carboxy)porphyrinato)manganese(III)
  • 4,4'-bis(manganese(III) 5,10,15-tris(4-sulfonatophenyl)porphin-20-yl)biphenyl
  • Biphenyl Compounds
  • Contrast Media
  • Coordination Complexes
  • Metalloporphyrins
  • Porphyrins
  • Manganese
  • Gadolinium